Sign In
Buy INBX
$95.22
+1.59 (+1.70%)
At Close: Jun 03, 2026
7,388 Shares in Inhibrx Biosciences, Inc. $INBX Acquired by Dynamic Technology Lab Private Ltd
04:06am, Friday, 13'th Mar 2026
Dynamic Technology Lab Private Ltd bought a new position in Inhibrx Biosciences, Inc. (NASDAQ: INBX) in the undefined quarter, according to its most recent disclosure with the Securities and Exchange
Inhibrx Announces Participation in Upcoming Scientific Conference
04:00pm, Monday, 02'nd Mar 2026
SAN DIEGO, March 2, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic
Inhibrx Biosciences, Inc. $INBX Shares Sold by Credit Industriel ET Commercial
04:28am, Monday, 16'th Feb 2026
Credit Industriel ET Commercial reduced its position in Inhibrx Biosciences, Inc. (NASDAQ: INBX) by 54.9% in the undefined quarter, according to the company in its most recent 13F filing with the Secu
Inhibrx: Ozekibart Beyond Chondrosarcoma, With Other Targeted Indications, Too
03:09pm, Tuesday, 13'th Jan 2026
Inhibrx Biosciences, Inc. remains a Strong Buy, driven by multiple near-term catalysts, notably the Q2 2026 BLA filing for ozekibart in chondrosarcoma. INBX expects to release pivotal progression-free
Why Inhibrx's Recent Strength May Not Be Built to Last
07:33am, Wednesday, 24'th Dec 2025
Inhibrx (NASDAQ: INBX) has staged a sharp rally after reporting positive topline results from its registrational trial of Ozekibart (INBRX-109) back in October 2025. The stock surged more than 150% in
SAN DIEGO , Dec. 16, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapeutics for oncol
Inhibrx Biosciences (NASDAQ:INBX) Reaches New 52-Week High – Here’s Why
04:14am, Friday, 05'th Dec 2025
Inhibrx Biosciences, Inc. (NASDAQ: INBX - Get Free Report) reached a new 52-week high during mid-day trading on Friday. The stock traded as high as $89.43 and last traded at $87.41, with a volume of 2
Stock Traders Buy High Volume of Inhibrx Biosciences Call Options (NASDAQ:INBX)
02:19am, Saturday, 15'th Nov 2025
Inhibrx Biosciences, Inc. (NASDAQ: INBX - Get Free Report) saw some unusual options trading activity on Friday. Stock traders bought 1,788 call options on the stock. This represents an increase of app
Inhibrx Reports Third Quarter 2025 Financial Results
06:00am, Friday, 14'th Nov 2025
SAN DIEGO , Nov. 14, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the third quarter of 2025. Following the completion
Inhibrx Announces Participation in Upcoming Scientific Conferences
04:01pm, Tuesday, 04'th Nov 2025
SAN DIEGO , Nov. 4, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeuti
Ethic Inc. Purchases New Shares in Inhibrx Biosciences, Inc. $INBX
03:21am, Friday, 31'st Oct 2025
Ethic Inc. purchased a new stake in shares of Inhibrx Biosciences, Inc. (NASDAQ: INBX) in the second quarter, according to its most recent disclosure with the SEC. The firm purchased 15,739 shares of
Inhibrx: Positive Ozekibart Data For Bone Cancer Leads To Q2 2026 BLA Filing
03:31pm, Friday, 24'th Oct 2025
Inhibrx Biosciences, Inc. delivered strong phase 2 results for ozekibart (INBRX-109) in advanced chondrosarcoma, doubling progression-free survival over placebo. INBX plans to file a Biologics License
Inhibrx shares surge after bone cancer drug slows disease progression in trial
06:39pm, Thursday, 23'rd Oct 2025
Inhibrx Biosciences said on Thursday its experimental drug helped slow the progression of a rare and aggressive bone cancer in a mid-stage trial, sending its shares surging over 70% in extended tradin
Ozekibart meets its primary endpoint in chondrosarcoma, demonstrating a statistically significant and clinically meaningful improvement in median progression-free survival compared to placebo Key se
– Event to be webcast live on Thursday, October 23, 2025 at 1:30 p.m. PT – SAN DIEGO , Oct. 22, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinic
